Merrick Ross Selected Research

Melanoma (Melanoma, Malignant)

1/2023	Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
1/2022	Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma.
1/2022	Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
10/2021	Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes.
3/2020	And Now for Something Completely Different: Immunotherapy Beyond Checkpoints in Melanoma.
1/2020	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
10/2018	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
1/2018	The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.
1/2017	Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials.
12/2016	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Merrick Ross Research Topics

Disease

19	Melanoma (Melanoma, Malignant) 01/2023 - 03/2002
16	Neoplasms (Cancer) 01/2022 - 04/2002
3	Fatigue 01/2022 - 09/2015
3	Breast Neoplasms (Breast Cancer) 04/2011 - 10/2005
2	Diarrhea 01/2022 - 10/2018
2	Chills 10/2018 - 09/2015
1	Dry Eye Syndromes (Dry Eye Syndrome) 01/2022
1	Exanthema (Rash) 01/2022
1	Necrosis 01/2020
1	Ischemia 01/2020
1	Fever (Fevers) 09/2015
1	Cellulitis 09/2015
1	Infections 01/2011
1	Febrile Neutropenia 01/2011
1	Thrombocytopenia (Thrombopenia) 01/2011
1	Pathologic Complete Response 01/2011
1	Tetanus 07/2010
1	Inflammation (Inflammations) 07/2010
1	Pain (Aches) 06/2005
1	Neoplasm Metastasis (Metastasis) 03/2002

Drug/Important Bio-Agent (IBA)

5	talimogene laherparepvecIBA 01/2023 - 09/2015
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2016 - 07/2010
2	IpilimumabIBA 01/2023 - 10/2018
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2008
2	pembrolizumabIBA 01/2022 - 01/2020
2	Immune Checkpoint InhibitorsIBA 10/2021 - 01/2020
2	VaccinesIBA 07/2010 - 08/2004
2	Peptides (Polypeptides)IBA 07/2010 - 08/2004
2	AntigensIBA 07/2010 - 08/2004
1	cyclopropapyrroloindoleIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	mavorixaforIBA 01/2022
1	Granzymes (Granzyme)IBA 01/2022
1	Messenger RNA (mRNA)IBA 10/2021
1	MicroRNAs (MicroRNA)IBA 10/2021
1	Keratins (Keratin)IBA 10/2021
1	Immune Checkpoint ProteinsIBA 10/2021
1	CytokinesIBA 03/2020
1	Immunomodulating AgentsIBA 03/2020
1	O-(6)-methylguanineIBA 01/2015
1	Temozolomide (Temodar)FDA LinkGeneric 01/2015
1	MethyltransferasesIBA 01/2015
1	Phenylalanine (L-Phenylalanine)FDA Link 01/2015
1	Mannose ReceptorIBA 04/2011
1	technetium-diethylenetriaminepentaacetic acid-mannosyl-dextranIBA 04/2011
1	Fluorouracil (Carac)FDA LinkGeneric 01/2011
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2011
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2011
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2011
1	incomplete Freund's adjuvantIBA 07/2010
1	Cytotoxins (Cytolysins)IBA 01/2010
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2008
1	Sorafenib (BAY 43-9006)FDA Link 12/2008
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 12/2008
1	Polymethyl Methacrylate (Sol)IBA 06/2005
1	Monoclonal AntibodiesIBA 08/2004
1	HMW-MAAIBA 08/2004
1	EpitopesIBA 08/2004
1	Coloring Agents (Dyes)IBA 04/2002
1	Interferon alpha-2 (Roferon-A)FDA Link 03/2002

Therapy/Procedure

9	Therapeutics 01/2022 - 05/2008
6	Immunotherapy 01/2022 - 09/2015
3	Lymph Node Excision (Lymph Node Dissection) 12/2019 - 04/2006
2	Mastectomy (Mammectomy) 01/2020 - 10/2005
2	Injections 10/2018 - 09/2015
1	Drug Therapy (Chemotherapy) 01/2015
1	Neoadjuvant Therapy 01/2011
1	Segmental Mastectomy (Lumpectomy) 10/2005
1	Cementoplasty 06/2005